Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASC10 in Mild or Moderate COVID-19 Patients
NCT05596045Phase 1Withdrawn
- Sponsor
- Ascletis Pharma Inc.
- Start
- Nov 2022
- Primary completion
- Mar 2023
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing ASC10 with Placebo (2 arms). Primary endpoints: Number of participants with Treatment Emergent Adverse Events and Pharmacokinetic parameters for ASC10, GLC01-700, and ASC10-A. Planned start Nov 2022; status: withdrawn.
02
Drugs
ASC10
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05596045.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05596045.